{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-122779","form_type":"8-K","ticker":"AMLX","cik":"0001658551","company_name":"Amylyx Pharmaceuticals, Inc.","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.131849+00:00","generated_at":"2026-05-30T03:36:49.146209+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Amylyx reports Q3 net loss of $72.7M; cash $234.4M; pipeline updates on AMX0035, avexitide, AMX0114","bullets":["Net loss of $72.7M ($1.07 loss per share) vs net income of $20.9M in Q3 2023; acquired IPR&D expense of $36.2M for avexitide.","Cash, cash equivalents and marketable securities of $234.4M as of Sept. 30, 2024, down from $309.8M at June 30, 2024; runway into 2026.","Positive Phase 2 HELIOS data for AMX0035 in Wolfram syndrome: met primary endpoint (C-peptide improvement), with stabilization across secondary measures.","Avexitide Phase 3 program in post-bariatric hypoglycemia on track to initiate in Q1 2025; topline data expected in 2026.","FDA placed clinical hold on AMX0114 ALS trial, requesting lower starting dose; Amylyx plans to start LUMINA trial in Canada by end of 2024/early 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-122779","json":"https://secwatch.observer/filing/0000950170-24-122779.json","markdown":"https://secwatch.observer/filing/0000950170-24-122779.md","text":"https://secwatch.observer/filing/0000950170-24-122779.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1658551/000095017024122779/0000950170-24-122779-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1658551/000095017024122779/amlx-20241107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:36:49.146209+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}